Journal of Cancer Survivorship

, Volume 2, Issue 3, pp 128–137

Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors


    • Department of Oncology, Institute of Clinical MedicineUniversity of Tromsø
  • N. Aass
    • Department of OncologyRikshospitalet Medical Center
  • S. D. Fosså
    • Department of Clinical Cancer ResearchRikshospitalet Medical Center
    • Medical FacultyUniversity of Oslo
  • O. Dahl
    • Section of Oncology, Institute of MedicineUniversity of Bergen
    • Department of OncologyHaukeland University Hospital
  • O. Klepp
    • Department of OncologySt. Olav University Hospital
  • E. A. Wist
    • Department of OncologyUllevål University Hospital
  • T. Wilsgaard
    • Institute of Community MedicineUniversity of Tromsø
  • R. M. Bremnes
    • Department of Oncology, Institute of Clinical MedicineUniversity of Tromsø
    • Department of OncologyUniversity Hospital of North Norway

DOI: 10.1007/s11764-008-0054-1

Cite this article as:
Haugnes, H.S., Aass, N., Fosså, S.D. et al. J Cancer Surviv (2008) 2: 128. doi:10.1007/s11764-008-0054-1



We examined if testicular cancer (TC) treatment is associated with any risk for cardiovascular morbidity or predicted mortality according to the SCORE model, in which a 10-year future risk of ≥5% for developing a fatal cardiovascular event qualify for high-risk status.


One thousand one hundred thirty-four TC survivors treated 1980–1994 participated in this study (1998–2002). Patients were categorised in four treatment groups: surgery (n = 225), radiotherapy (n = 445), and two chemotherapy groups: cumulative cisplatin dose ≤850 mg (n = 375) and >850 mg (cis>850, n = 89). Patients with cardiovascular disease, diabetes or SCORE ≥5% constituted a high-risk group, and those with SCORE >1% an intermediate/high risk group.


Age-adjusted mean SCORE was 0.93% for the surgery group. In comparison, chemotherapy treated patients had significantly higher SCORE (1.07%, p = 0.01). Only 15% of patients were scored to be at high-risk, while 53% qualified for the intermediate/high risk group. Patients in the cis>850 group had increased odds for having intermediate/high risk, compared with the surgery group (OR 3.4, 95% CI 1.3–8.7). Only 23 cardiovascular events had occurred since the testicular cancer diagnosis.


The SCORE model indicates that patients treated with cisplatin-based chemotherapy have a significantly increased future risk of a fatal cardiovascular event.

Implications for cancer survivors

TC survivors should be followed regularly with respect to cardiovascular risk profile beyond the routine 10-year clinical follow-up.


Testicular cancerCisplatinCardiovascularMortalityMorbiditySCORE

Copyright information

© Springer Science+Business Media, LLC 2008